Myocardial perfusion and ACE inhibition

B J Gersh¹

Affiliations

Comment

B J Gersh. Rev Cardiovasc Med. 2000 Fall.

. 2000 Fall;1(2):75-8.

B J Gersh¹

No abstract available

Comment on

Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.
Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Gibson CM, et al. Circulation. 2000 Jan 18;101(2):125-30. doi: 10.1161/01.cir.101.2.125. Circulation. 2000. PMID: 10637197 Clinical Trial.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators, et al. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301. N Engl J Med. 2000. PMID: 10639539 Clinical Trial.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
[No authors listed] [No authors listed] Lancet. 2000 Jan 22;355(9200):253-9. Lancet. 2000. PMID: 10675071 Clinical Trial.